← All trials
NCT05783557
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2023
- Primary completion
- Dec 1, 2024
- Completion date
- Jun 1, 2025
- First posted
- Mar 24, 2023
- Last posted
- Mar 24, 2023
- Enrollment
- 398
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Lead sponsor
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.